Shares of Santa Monica’s Kite Pharma surged nearly 30 percent in after-hours trading Monday after the clinical-stage biotech company announced the publication of clinical results demonstrating the potential of its drug to treat aggressive non-Hodgkin’s lymphoma, the Business Journal reported.